Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543007 | 0.90 | CYP2A6 (0.48) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL7842540 | 0.90 | CYP2A6 (0.48) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL18549966 | 0.87 | CYP2A6 (0.46) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL6075548 | 0.80 | CYP2A6 (0.40) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL3807297 | 0.79 | NOTUM (0.42) | CYP2A6TSHRIDO1MAPTMAPK1 | |
| SCHEMBL29883244 | 0.78 | CYP2A6 (0.67) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL29802156 | 0.78 | CYP2A6 (0.67) | CYP2A6LMNATSHRNPC1RAB9A | |
| SCHEMBL671133 | 0.78 | CYP2A6 (0.67) | CYP2A6LMNATSHRNPC1RAB9A | |
| Ammonia Solution, Strong SCHEMBL735046 | 0.76 | CYP2A6 (0.63) | CYP2A6LMNATSHRNPC1RAB9A | |
| Hydrogen Sulfide SCHEMBL8574751 | 0.76 | CYP2A6 (0.63) | CYP2A6LMNATSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4165033-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-04-19 | — | — | EP | claimed |
| WO-2021249449-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-12-16 | — | — | WO | claimed |
| EP-3337787-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Changzhou Jiekai Pharmatech Co. Ltd. (CN) | 2018-06-27 | — | — | EP | claimed |
| WO-2017028314-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-02-23 | — | — | WO | claimed |
| EP-2782903-B1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | claimed |
| EP-2782903-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-01 | — | — | EP | claimed |
| US-8729061-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | claimed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| US-20130137687-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | claimed |
| WO-2013076063-A1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-30 | — | — | WO | claimed |
| CN-101951909-B | Pyridopyrazinones derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH | 2013-05-15 | — | — | CN | claimed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | claimed |
| CN-101951909-A | As the pyrido-pyrazine ketones derivant of insulin secretion stimulant, the method that obtains them and the purposes in the treatment diabetes thereof | MERCK PATENT GMBH | 2011-01-19 | — | — | CN | claimed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | claimed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | claimed |
| CN-115124440-B | Preparation method of prothioconazole intermediate | 江苏七洲绿色科技研究院有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4165033-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-5051447-A | Applying aromatic oximes to plants, seeds or soils | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | disclosed |
| US-4952720-A | Ortho-substituted benzyl carboxylates and fungicides which contain these compounds | BASF AKTIENGSELLSCHAFT (DE) | 1990-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CYP2A6 1212/4885LMNA 3920/4885TSHR 2043/4885 |
| US-20130137687-A1 | NOVEL PYRROLIDINE DERIVATIVES | PYCR1, PRMT7, PRLHR | CYP2A6 1123/4885LMNA 4095/4885TSHR 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.